Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-23 02:01 UTC

BIOMED PULSE

Tuesday, September 23, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in DRC history, with sustained cross-border transmission into Uganda still ongoing. [1]

Mood: Grave on the outbreak front; longevity science offers measured optimism with new bone-repair and senescence-targeting research moving forward. [2] [3]

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA VIRUS DISEASE — DRC AND UGANDA (ACTIVE, INTENSIFYING)

  • As of September 10, 2026, 61 health zones are confirmed affected across Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo provinces; the Kayna health zone in North Kivu is the most recently added. [1]
  • The outbreak has expanded from 54 to 61 affected health zones since the August 14 Disease Outbreak News, with six additional health zones reporting cases in the August 28 update alone. [4] [1]
  • As of July 15, 2026, a cumulative 2,124 confirmed cases and 828 deaths were on record from DRC, representing a case fatality burden that has grown rapidly since the outbreak was first detected in Mongbwalu Health Zone, Ituri Province, on May 5, 2026. [5]
  • WHO characterized the outbreak on August 14 as "expanding faster than any previous Ebola outbreak" in DRC history, driven by sustained transmission in urban and semi-urban corridors. [6]
  • Cross-border transmission into Uganda was confirmed early in the outbreak; DRC and Uganda jointly declared the Bundibugyo virus disease outbreak on May 15, 2026, following confirmation by the Institut National de Recherche Biomédicale. [7]
  • Enhanced Ebola airport entry screening was initiated at Washington-Dulles International Airport on May 21 and later expanded to Hartsfield-Jackson Atlanta International Airport on May 23, 2026. [8] [9]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY (ONGOING MONITORING)

  • The fifth WHO Disease Outbreak News update (July 2, 2026) confirmed this is an Andes hantavirus (ANDV) cluster originating from the cruise ship M/V Hondius, first reported to WHO on May 2, 2026, with cases identified in multiple countries. [10]
  • A CDC transcript from June 24, 2026, confirms continued federal monitoring of the hantavirus response; the outbreak initially involved seven cases aboard a vessel carrying 147 passengers and crew.

DRUG-RESISTANT BACTERIA — UNITED STATES (NEW REPORT)

  • A CDC report released September 23, 2026, found a dramatic increase in dangerous drug-resistant bacteria circulating in the United States.
  • Separately, tigecycline — one of last-resort antibiotics used against multidrug-resistant organisms — received supplemental approvals from both Sandoz (ANDA091620) and Meitheal (ANDA214020), reflecting continued regulatory activity around this drug class.

ANIMAL RABIES — UNITED STATES (ELEVATED ACTIVITY)

  • CDC issued a statement on September 10, 2026, noting increases in recent animal rabies activity and associated human exposures across the United States.

WEST NILE VIRUS — UNITED STATES (EARLY RECORD SEASON)

  • CDC reported an early West Nile season with record case counts as of July 1, 2026, urging Americans to use mosquito bite prevention measures.

MEASLES — BANGLADESH (ONGOING LARGE-SCALE OUTBREAK)

  • As of April 23, 2026, WHO reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases spreading across 58 of 64 districts in all eight divisions of Bangladesh.

NIPAH VIRUS — INDIA (SPORADIC CASE, KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed case of Nipah virus infection in Kozhikode district; the adult male developed symptoms May 30 and was hospitalized June 10 with neurological presentation.

YELLOW FEVER — GLOBAL (CONTINUED AMERICAS TRANSMISSION)

  • From January 1 to May 26, 2026, six countries reported 79 human infections; transmission activity in the Americas that surged in 2025 carried into 2026.

CYCLOSPORIASIS — UNITED STATES (TACO BELL ICEBERG LETTUCE)

  • Shredded iceberg lettuce served at Taco Bell locations was confirmed as the source of Cyclospora infections across five states as of July 17, 2026, with 1,644 people sickened; the outbreak subsequently expanded to four additional states by July 24.

CONGENITAL SYPHILIS — UNITED STATES (12TH CONSECUTIVE ANNUAL INCREASE)

  • New CDC data released September 24, 2026, show U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024, signaling a continued failure to interrupt vertical transmission.

🧬 LONGEVITY & AGING

MRNA LIPID NANOPARTICLES FOR AGE-RELATED BONE REPAIR

  • Cheng et al. (Bioact Mater, August 20, 2026) describe a dual-targeting mRNA lipid nanoparticle (LNP) system that restores ABCA1-dependent cholesterol homeostasis in aged bone tissue — ABCA1 is a transporter that moves cholesterol out of cells, and its dysfunction accumulates in aging bone — promoting structural repair of age-related bone defects. [2]
  • A complementary study by Zhu et al. (Bioact Mater, August 27, 2026) demonstrates that BMP-2-driven osteo-organoid formation — essentially a miniature bone-like structure grown from stem cells — retains key osteogenic support features and promotes bone repair even after total-body irradiation, which typically devastates bone-forming cells.
  • Yin et al. (Bioact Mater, August 30, 2026) report a quercetin-derived carbon dot modified ZIF-8 nanocomposite hydrogel incorporating M2 macrophage-derived migrasomes that responds to the osteoporotic bone microenvironment to drive regeneration, linking anti-inflammatory macrophage biology to bone aging.

SENESCENCE IN SKIN AND HAIR FOLLICLE CELLS

  • Jia et al. (Genes Dis, published online) show that ionizing radiation drives senescence in dermal papilla cells — the hair follicle cells essential for hair growth — by inhibiting the FOXM1-KIF20A pathway, a transcription factor-motor protein axis that normally keeps cells cycling; blocking this pathway accelerates aging-associated hair loss.
  • Koutsoukos et al. (Methods Mol Biol, forthcoming 2027) characterize the Senescence-Associated Secretory Phenotype (SASP) — the inflammatory cocktail released by senescent cells that damages neighboring tissue — in both primary skin cells and iPSC-derived skin cells using multiplex assay platforms, providing a standardized toolkit for senolytic research. [3]

MOLECULAR HYDROGEN AS A RADIATION AND AGING PROTECTOR

  • Ichikawa et al. (Med Gas Res, September 12, 2026) review evidence that molecular hydrogen (H2) gas may act as a selective antioxidant against hydroxyl radicals produced by environmental radiation, positioning it as a potential low-cost countermeasure against radiation-induced cellular aging and DNA damage.

HIGH-DOSE INFLUENZA VACCINE AND FRAILTY IN OLDER ADULTS

  • Analysis from the randomized DANFLU-2 trial (Espersen et al., Lancet Healthy Longev) finds that high-dose influenza vaccine is more effective than standard-dose at preventing hospitalization in frailer older adults, consistent with the principle that biologically older immune systems need a stronger antigen stimulus; a companion editorial by Verschoor and Kuchel terms this the "frailty-influenza paradox."

HIP FRACTURE SURGERY ANAESTHESIA IN OLDER PATIENTS

  • A multicenter randomized clinical trial by Kowark et al. (Lancet Healthy Longev) conducted in Germany compared spinal versus general anaesthesia for hip fracture surgery in older patients, directly addressing a highly debated question in geriatric perioperative medicine; an accompanying editorial asks whether it is "time to put the question to sleep."

DEPRESCRIBING TRIALS AND OLDER ADULTS

  • Two independent commentaries in Lancet Healthy Longev (Hwang, Boockvar, Steinman; and Van der Linden) argue that deprescribing trials — studies testing whether stopping medications in older adults improves outcomes — must first establish a clear mechanistic rationale before selecting a trial design, warning against one-size-fits-all approaches in polypharmacy-laden elderly populations.

ATHEROSCLEROSIS: SINGLE-CELL DISCOVERY OF NARCICLASINE

  • Wang et al. (Genes Dis) used single-cell RNA sequencing to identify narciclasine — a plant alkaloid — as a dual inhibitor of VCAM-1 and ICAM-1, two adhesion molecules that recruit inflammatory cells to arterial plaques; the finding offers a potentially novel small-molecule approach to cardiovascular aging.

NECROPTOSIS AND ENDOPLASMIC RETICULUM STRESS IN AGING DISEASE

  • Li et al. (Genes Dis) describe how unfolded protein response activation during endoplasmic reticulum stress regulates necroptosis — an inflammatory form of cell death — linking ER stress, a hallmark of cellular aging, to a range of age-associated diseases including neurodegeneration and metabolic disorders.

INTERVERTEBRAL DISC REGENERATION

  • Jiang et al. (Bioact Mater, September 3, 2026) present a comprehensive biomaterials roadmap for intervertebral disc regeneration through niche reprogramming and precision therapeutics, targeting a major driver of chronic pain and disability in aging populations.

💊 NEW CURES & APPROVALS

TIGECYCLINE SUPPLEMENTAL APPROVALS (ANTI-INFECTIVE, LAST-RESORT ANTIBIOTIC)

  • Sandoz received a supplemental approval (ANDA091620) for generic Tigecycline, a glycylcycline antibiotic used against extensively drug-resistant gram-negative and gram-positive organisms in serious hospital infections.
  • Meitheal Pharmaceuticals also received a supplemental approval (ANDA214020) for Tigecycline, expanding the generic manufacturing base for this critically important antibiotic class at a time when CDC reports rising drug-resistant bacteria.

TRUQAP (CAPIVASERTIB) — ASTRAZENECA (BREAST CANCER)

  • AstraZeneca received a supplemental approval (NDA218197) for Truqap (capivasertib), an AKT kinase inhibitor used in combination with fulvestrant for hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations.

XELJANZ / XELJANZ XR (TOFACITINIB CITRATE) — PFIZER / PF PRISM CV (JAK INHIBITOR)

  • Pfizer and PF Prism CV received supplemental approvals across three application numbers (NDA203214, NDA208246, NDA213082) for tofacitinib citrate, a JAK inhibitor indicated for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis.

IBTROZI (TALETRECTINIB ADIPATE) — NUVATION BIO (LUNG CANCER)

  • Nuvation Bio received a supplemental approval (NDA219713) for Ibtrozi (taletrectinib adipate), a next-generation ROS1/NTRK inhibitor for non-small cell lung cancer.

JYNARQUE (TOLVAPTAN) — OTSUKA (POLYCYSTIC KIDNEY DISEASE)

  • Otsuka received a supplemental approval (NDA204441) for Jynarque (tolvaptan), a vasopressin V2-receptor antagonist that slows kidney cyst growth in adults with autosomal dominant polycystic kidney disease at risk of rapid progression.

EPINEPHRINE — DIFGEN PHARMACEUTICALS (ANAPHYLAXIS)

  • Difgen Pharmaceuticals received an original approval (ANDA220657) for an epinephrine injection product for emergency treatment of type I allergic reactions including anaphylaxis.

🧪 CLINICAL TRIALS

KARXT FOR ALZHEIMER'S DISEASE PSYCHOSIS — ADEPT-4 (NCT06585787)

  • The ADEPT-4 trial, registered September 22, 2026, is evaluating KarXT (xanomeline-trospium, a muscarinic receptor agonist) for the treatment of moderate to severe psychosis in adults with mild to severe Alzheimer's Disease; KarXT was previously FDA-approved for schizophrenia.

EFGARTIGIMOD FOR AUTOIMMUNE ENCEPHALITIS — POLARIS (NCT07583641)

  • The POLARIS study, registered September 22, 2026, is a four-part trial evaluating efgartigimod PH20 SC (an FcRn blocker that lowers pathogenic IgG antibodies) for autoimmune encephalitis in participants aged 12 and older; the trial includes a randomized placebo-controlled phase.

DUPILUMAB FOR COPD AIRWAY INFLAMMATION — PHASE 4 (NCT07053423)

  • LPS18583 is a multinational, randomized, double-blind, placebo-controlled Phase 4 study evaluating dupilumab (IL-4/IL-13 receptor blocker, already approved for asthma and atopic dermatitis) on airway inflammation, resistance, remodeling, and mucus plugging in adults aged 40 to 85 years with chronic obstructive pulmonary disease.

FOSTAMATINIB IN LUNG TRANSPLANT PATIENTS — SIMILAR TRIAL (NCT06948097)

  • The SIMILAR trial is evaluating the Syk kinase inhibitor fostamatinib for safety and tolerability in lung transplant patients who have developed donor-specific antibodies (DSA), an immune mechanism that currently lacks approved therapy and drives graft loss; lung transplant recipients typically survive only 6-7 years.

BPL-1357 UNIVERSAL INFLUENZA VACCINE — H1N1 CHALLENGE STUDY (NCT07215858)

  • A controlled human infection model study is testing BPL-1357, a broadly protective influenza vaccine candidate, against H1N1 influenza virus challenge in healthy volunteers, targeting pandemic preparedness gaps where seasonal vaccines fall short.

DUAL-TASK EXERCISE FOR FALL PREVENTION IN NURSING HOME RESIDENTS (NCT07823166)

  • A randomized controlled study comparing motor versus cognitive dual-task exercise programs over eight weeks on fall risk, balance, and gait in older nursing home residents was registered September 22, 2026.

HORTICULTURAL THERAPY FOR ANXIETY IN OLDER ADULTS (NCT07826013)

  • A randomized controlled pre-test/post-test trial registered September 22, 2026, is examining whether a structured horticultural therapy program reduces anxiety and improves quality of life in older adults.

BASE-EDITED STEM CELL GENE THERAPY FOR WHIM SYNDROME (NCT07775313)

  • A trial registered September 22, 2026, is testing base-edited hematopoietic stem/progenitor cell gene therapy to correct the CXCR4 gain-of-function mutation underlying WHIM syndrome, a rare immunodeficiency causing severe recurrent infections; base editing allows precise single-letter DNA correction without cutting the double strand.

ALPHA-LIPOIC ACID PLUS MIRABEGRON FOR OBESITY (NCT05713799)

  • A NIH-sponsored trial is evaluating the combination of alpha-lipoic acid (antioxidant supplement) and mirabegron (a beta-3 adrenergic agonist that activates metabolically active brown fat) in women and men with obesity, targeting a mechanistically distinct, non-addictive approach to metabolic disease.

📢 PUBLIC HEALTH

LISTERIA OUTBREAK — PREPARED MEALS (ONGOING, EXPANDING)

  • CDC expanded the Listeria monocytogenes outbreak linked to prepared meals to include additional food products, with 3 new illnesses and 1 additional death reported as of September 26, 2026; consumers are urged to check refrigerators and freezers for any recalled products.

CONGENITAL SYPHILIS AT 12-YEAR HIGH

  • CDC data released September 24, 2026, confirm syphilis in newborns rose for the 12th straight year in 2024, underscoring persistent gaps in prenatal screening and treatment for a fully preventable condition.

SALMONELLA — METABOLIC MEALS HOME DELIVERY (ACTIVE INVESTIGATION)

  • As of September 5, 2026, 16 people across 10 states became ill with the same Salmonella strain linked to Metabolic Meals home delivery food products; an investigation is ongoing.

CDC TRAVELER-BASED GENOMIC BIOSURVEILLANCE EXCEEDS 1 MILLION PARTICIPANTS

  • CDC's voluntary air travel genomic surveillance program surpassed one million enrolled participants as of January 30, 2026, expanding early-warning capacity to detect novel or emerging pathogen variants in travelers entering the United States.

ANIMAL RABIES HUMAN EXPOSURE INCREASE

  • CDC's September 10, 2026, statement alerts the public and clinicians to a recent uptick in animal rabies activity and associated human exposure events, reminding travelers and pet owners about post-exposure prophylaxis protocols.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. A dual-targeting mRNA lipid nanoparticle restores ABCA1-depend… — Europe PMC — Longevity
  3. Characterization of the Senescence-Associated Secretory Phenot… — Europe PMC — Longevity
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  7. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260923-02-v84 · 2026-09-23 02:01 UTC · pulse.uzylab.com

Read next